Intuitive Surgical shares fall as procedure growth slows despite Q2 earnings beat

Intuitive Surgical (ISRG) shares fell about 11% after Q2 results beat expectations but US procedure growth slowed. Revenue rose to $2.89B (vs $2.82B expected) and adjusted EPS was $2.80 (vs $2.51 expected). US procedure growth was 12% vs 14% in Q1. For 2026, da Vinci growth guidance stayed 13.5% to 15.5%, nearer the midpoint.

Original reporting
Published Jul 17, 2026, 7:45 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 17, 2026, 7:50 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Intuitive Surgical shares fall as procedure growth slows despite Q2 earnings beat — source image
Decision brief

The 30-second read

$ISRGBearishMed
01

Why it matters

Near-term valuation pressure is driven by the gap between implied 2026 procedure growth (about 14.5%) and analyst expectations (~15.3%), alongside the US growth deceleration from 14% to 12% quarter over quarter.

02

Market read

This is a classic beat-but-miss on growth quality story, where guidance and US procedure trends dominate the tape.

03

What to watch

Tariff impact is quantified as about 1% on gross margin, and systems/instruments growth (systems revenue up, installed base rising) may support longer-term adoption even if near-term procedures are deferred.

Relevance 7/10Novelty 6/10Timing: post-Q2 earnings reaction, Friday selloff

Background

ISRG reported Q2 results that beat consensus, but investors focused on moderating US procedure growth tied to deferred treatments and insurance coverage changes after ACA premium subsidies expired.

Company-level read

Ticker impact

$ISRGBearishHigh confidence
Context

ISRG shares fell about 11% after Q2 beat, but US procedure growth slowed to 12% from 14% and full-year outlook was cautious.

Expected impact

Bearish bias for the next several sessions as investors reprice the US growth trajectory and the implied 2026 procedure growth rate.

Evidence & confidence

The article attributes the selloff directly to slower US procedure growth and a full-year outlook that comes in below analysts' expectations (about 14.5% vs ~15.3%).

Market effects

Robotic surgery peers may face read-across risk if investors generalize the US procedure growth slowdown as demand softness.

US-focused procedure growth deceleration is the key driver, potentially weighing on US medtech sentiment more than ex-US.

Worldwide growth guidance held, but the market is trading the US mix and insurance-related deferrals.

Counterpoint

The company maintained worldwide da Vinci growth guidance and reaffirmed margins and expense growth, suggesting the slowdown could be temporary timing effects rather than structural demand loss.

Key entities

  • Intuitive Surgical

    Robotic surgery company whose Q2 beat was offset by slower US procedure growth and a cautious full-year outlook.

Related articles

$ISRGMed

Oppenheimer Just Upgraded Intuitive Surgical Stock. Here's Why.

Oppenheimer upgraded Intuitive Surgical (ISRG) from “Perform” to “Outperform” and set a $500 price target, implying about 24.6% upside, citing robotic surgery growth and AI plans. The article notes Q2 revenue of $2.89B (vs $2.82B expected), EPS $2.80, da Vinci and Ion procedure growth, and ISRG guidance for da Vinci growth of 13.5% to 15.5%.

$ISRGMed

Why is Intuitive Surgical stock gaining today?

Investing.com reports Intuitive Surgical (ISRG) rose about 0.8% in pre-open after Oppenheimer upgraded it to Outperform from Perform and set a $500 price target. Oppenheimer and Bank of America Securities issued Buy ratings, citing da Vinci’s competitive position and Per Click Model. The article also notes ISRG Q2 2026 EPS of $2.80 vs $2.51 consensus.

$JNJMed

Can Johnson & Johnson (JNJ) Challenge Intuitive Surgical (ISRG) After Ottava’s FDA Approval?

Johnson & Johnson (JNJ) received FDA De Novo authorization for its OTTAVA robotic surgical system and is entering U.S. soft-tissue robotic surgery. OTTAVA is authorized for multiple upper-abdominal procedures, with a selective U.S. launch and an ongoing inguinal hernia trial. The article compares JNJ’s entry with Intuitive Surgical (ISRG) and its da Vinci 5 installed base.

$ISRGMed

Intuitive Surgical's 34% Plunge Splits Analysts: DCF Says Fair Value, Bernstein Sees 83% Upside — BigGo Finance

Intuitive Surgical (ISRG) shares fell 34% YTD after guidance for 2026 da Vinci procedure growth of 13.5% to 15.5% versus about 18% expected. The stock trades at $373.71, below an average analyst target of $477.25. A DCF estimates fair value near $408, while Bernstein cites an $685 target. Q2 2026 results: non-GAAP EPS $2.80, revenue $2.89B.

$ISRGMed

UBS starts medtech coverage, favors Intuitive Surgical and Enovis By Investing.com

UBS initiated coverage of four U.S. medtech firms. It assigned Buy ratings to Intuitive Surgical (ISRG) with a $500 price target and Enovis (ENOV) with a $51 target, citing growth drivers and improving fundamentals. UBS gave Inspire Medical Systems (INSP) a Sell rating with a $39 target and Integra LifeSciences (IART) a Neutral rating with a $19 target, citing competition, reimbursement and limited catalysts.

Intuitive Surgical shares fall as procedure growth slows despite Q2 earnings beat — alphai